Tuesday, January 31, 2023
  • Login
CEO North America
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
CEO North America
No Result
View All Result

Astrazeneca reports 28% revenue growth on COVID windfall

in News
Pfizer seeks emergency use authorization for novel covid-19 oral antiviral candidate
Share on FacebookShare on Twitter

UK-based pharmaceutical company Astrazeneca reported $25.4 billion in revenues in its 3Q21 earnings report, up 28% from 2020. A $2.2 billion dollar windfall in COVID vaccine revenues accounted for 11% of the rise in total revenues with the remaining 17% of growth coming from other medicines.

Gains in oncology which was up 16%, cardiovascular, renal and metabolism which was up 10% and respiratory and immunology which was up 12% accounted for the rest of the revenue rise over 2021.

According to the company it had released 1.5 billion doses of Vaxzevria, its COVID-19 vaccine, for global supply as of the end of September of which more than 145 million was distributed to the COVAX collaboration led by the WHO to ensure the availability of vaccines in low-income countries.

The company reported that one of its trial drugs, AZD7442, has had multiple positive Phase III results for COVID prevention and treatment, showing a 77% reduction of risk of symptomatic COVID-19 and a 50% risk reduction at 7 days from the disease’s onset. Astrazeneca also noted that Vaxzevria offers 91% protection against death due to the Delta variant.

Geographically growth was driven by the US market, which showed 53% year-over-year 3Q21 gains, flowed by Europe with 36% gains over the same period.

Tags: AstraZenecaCOVID windfallrevenue growth

Related Posts

Payments firm paypal to lay off 7% of its workforce to cut costs
News

Payments firm PayPal to lay off 7% of its workforce to cut costs

Apple workplace rules violate u. S. Labor law, agency finds
News

Apple workplace rules violate U.S. labor law, agency finds

Walmart, cvs health adjust pharmacy hours due to labor crunch
News

Walmart, CVS Health adjust pharmacy hours due to labor crunch

Volvo group north america faces $130m civil penalty
News

Volvo Group North America faces $130M civil penalty

Tiktok ceo to testify before u. S. Congress over security concerns
News

TikTok CEO to testify before U.S. Congress over security concerns

 us debt not a crisis yet according to economists
News

 US debt not a crisis yet according to economists

Ford recalls 462,000 vehicles for rear camera display failure
News

Ford recalls 462,000 vehicles for rear camera display failure

Us inflation and consumer spending fall for 2  straight months
News

US inflation and consumer spending fall for 2 straight months

Intel’s ‘historic collapse’ triggers selloff in chip stocks
News

Intel’s ‘historic collapse’ triggers selloff in chip stocks

Morgan stanley penalizes employees for whatsapp breaches
News

Morgan Stanley penalizes employees for WhatsApp breaches

No Result
View All Result

Recent Posts

  • Payments firm PayPal to lay off 7% of its workforce to cut costs
  • Apple workplace rules violate U.S. labor law, agency finds
  • Helping Gen Z Employees Find Their Place at Work
  • Why Your Talent Team Needs Scenario Planning
  • Walmart, CVS Health adjust pharmacy hours due to labor crunch

Recent Comments

    Archives

    Categories

    • Art & Culture
    • Business
    • CEO Interviews
    • CEO Life
    • Editor´s Choice
    • Entrepreneur
    • Environment
    • Food
    • Health
    • Highlights
    • Industry
    • Innovation
    • Issues
    • Management & Leadership
    • Multimedia
    • News
    • Opinion
    • PrimeZone
    • Printed Version
    • Travel
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

    Editorials – stuart.james@ceo-na.com

    Editor-In-Chief – caroline.sposto@ceo-na.com

    Editorials – editorials@ceo-na.com

    Advertising – media@ceo-na.com

    NEW YORK

    110 Wall St.,
    3rd Floor
    New York, NY.
    10005
    USA
    +1 212 432 5800

     

    MEXICO CITY

    Paseo de la Reforma 296,
    Floor 38
    Mexico City
    06600
    MEXICO

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

    Editorials –
    stuart.james@ceo-na.com

    Editor-In-Chief –

    caroline.sposto@ceo-na.com

    Editorials – editorials@ceo-na.com

    Advertising –
    media@ceo-na.com

    NEW YORK

    110 Wall St.,
    3rd Floor
    New York, NY.
    10005
    USA
    +1 212 432 5800

    MEXICO CITY

    Paseo de la Reforma 296,
    Floor 38
    Mexico City
    06600
    MEXICO

    CEO North America © 2022 - Sitemap

    No Result
    View All Result
    • Home
    • Business
      • Entrepreneur
      • Industry
      • Innovation
      • Management & Leadership
    • CEO Interviews
    • CEO Life
      • Art & Culture
      • Food
      • Health
      • Travel
      • Environment
    • Opinion
    • News
    • Multimedia

    © 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In